期刊文献+

Preparation and Crystal Modification of Ibuprofen-Loaded Solid Lipid Microparticles 被引量:4

布洛芬固体脂质微颗粒的制备及其晶体构型研究
下载PDF
导出
摘要 An emulsion-congealing technique is used to prepare solid lipid microparticles (SLM) containing ibuprofen with glyceryl behenate, tripalmitin and beewax as excipients. The difference of the solubility parameters between the excipients and ibuprofen are used to analyze their compatibility. Both the solubility parameter analysis and the experimental results show that glyceryl behenate is the best among the three excipients. The solid particles disperse well in aqueous phase when the drug loading reaches 10% (relative to lipid only). Glycerides exhibit marked polymorphism and their rapid rates of crystallization accelerate the formation of metastable crystal modification. The metastable crystal modification characterizes high drug loading capacity but less stability. Increasing the content of lipophilic drug in a lipid matrix facilitates the transformation of excipients to more stable polymorphic forms.
出处 《Chinese Journal of Chemical Engineering》 SCIE EI CAS CSCD 2006年第4期518-525,共8页 中国化学工程学报(英文版)
基金 Supported by the National Natural Science Foundation of China (No.20536020, No.20476033), the China Distinguished Young Scientist Fund (No.20225620) and Guangdong Province Science Fund (No.04020121).
关键词 solid lipid microparticles crystal modification solubility parameter drug loading capacity IBUPROFEN 布洛芬 固体脂质微颗粒 制备 晶体构型 溶解参数 药物
  • 相关文献

参考文献27

  • 1Mehnert, W., Mader, K., "Solid lipid nanoparticles production, characterization and applications", Adv. Drug Deliv. Rev., 47, 165-196(2001).
  • 2Gasco, M.R., "Method for producing solid lipid microspheres having a marrow size distribution", US Pat.,5250236 (1993).
  • 3Müller, R.H., Radtke, M., Wissing, S.A., "Solid lipid nanoparticles (SLN) and nanostructured lipid carriers(NLC) in cosmetic and dermatological preparations",Adv. Drug Deliv. Rev., 54(Suppl. 1), S131-S155(2002).
  • 4Hu, F.Q., Hong, Y., Yuan, H., "Preparation and characterization of solid lipid nanoparticles containing peptide",Int. J. Pharm., 273, 29-35(2004).
  • 5Schwarz, C., Mehnert, W., Lucks, J.S., Muller, R.H.,"Solid lipid nanoparticles (SLN) for controlled drug delivery Ⅰ. Production, characterisation and sterilization", J.Control. Release, 30, 83-96(1994).
  • 6Lamprecht, A., Bouligand, Y., Benoit, J.P., "New lipid nanocapsules exhibit sustained release properties for amiodarone", J. Control. Release, 84, 59-68(2002).
  • 7Venkateswarlu, V., Manjunath, K., "Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles", J. Control. Release, 95, 627-638(2004).
  • 8Mühlen, A.Z., Mühlen, E.Z., Niehus, H., Mehnert, W.,"Atomic force microscopy studies of solid lipid nanoparticles", Pharm. Res., 13(9), 1411-1416(1996).
  • 9Liu, J., Xiao, Y., Allen, C., "Polymer-drug compatibility:A guide to the development of delivery systems for the anticancer agent, ellipticine", J. Pharm. Sci., 93(1),132-143(2004).
  • 10Six, K., Verreck, G., Peeters, J., Brewster, M., Mooter,G.V.D., "Increased physical stability and improved dissolution properties of itraconazole, a class Ⅱ drug, by solid dispersions that combine fast- and slow-dissolving polymers", J. Pharm. Sci., 93 (1), 124-131(2004).

同被引文献8

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部